A further bispecific, humanized IgG1 antibody that is definitely beneath investigation is zenocutuzumab (MCLA-128), which acts via two impartial mechanisms of motion: inhibition of HER2–HER3 signalling and elimination of tumour cells by way of ADCC. MCLA-128 features through a ‘dock and block’ system whereby a person arm from the antibody bin